---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026357"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:00.132875+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin Q2 2025 cash $7.6M; R&D expense down to $3.6M; MIRACLE trial data readout expected by year-end

## Summary
- Cash and equivalents $7.6M at June 30, 2025, expected to fund operations only into Q4 2025.
- R&D expense $3.6M for Q2 2025, down $0.5M from $4.1M in Q2 2024 due to reduced clinical trial activity.
- G&A expense flat at $2.1M; no revenue reported for the quarter.
- MIRACLE Phase 2B/3 trial expanded to 4 active sites in US, EU, and Georgia; 20+ additional sites expected by end of Q3 2025.
- Anticipated unblinded data readout from first 45 subjects in MIRACLE Part A before end of 2025.

## SEC filing metadata
- accession: 0001437749-25-026357
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/0001437749-25-026357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/mbrx20250811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026357
- JSON: https://secwatch.observer/filing/0001437749-25-026357.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.